Lundbeck to present at two upcoming investor conferences
H. Lundbeck A/S (Lundbeck) today announced its presentations at two upcoming investor conferences, where Lundbeck’s management will provide an overview of the company. Presentation slides will become available in the investor section of the company’s web site at www.lundbeck.com.
On Monday, 9 January 2012, Lundbeck will present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco at 8:00 a.m. local time. Lundbeck will be presented by Ulf Wiinberg, President and CEO.
Also on Monday, 9 January 2012, Lundbeck will present at SEB Enskilda Nordic Seminar Prologue in Copenhagen at 12:30 p.m. local time. Lundbeck will be presented by Ole Chrintz, Senior Vice President, International Markets.
Lundbeck contacts
| Investors: | ||
| Palle Holm Olesen | Jacob Tolstrup | |
| Chief Specialist, Investor Relations | Vice President | |
| palo@lundbeck.com | jtl@lundbeck.com | |
| +45 36 43 24 26 | +1 847 282 5713 | |
| Magnus Thorstholm Jensen | ||
| Investor Relations Officer | ||
| matj@lundbeck.com | ||
| +45 36 43 38 16 | ||
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and Huntington’s, Alzheimer’s and Parkinson’s diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world’s leading pharmaceutical companies working with brain disorders. In 2010, the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD 2.6 billion). For more information, please visit www.lundbeck.com.